Nice

  1. Guideline evidence on self-harm risk tools is described as uncertain
    Critical analysis of NICE self-harm guidelines' methodological limitations, examining evidence gaps in risk assessment tool recommendations and the role of committee judgment versus empirical data.
  2. Rivaroxaban controversy linked to synthetic certainty
    Analysis of regulatory closure and synthetic certainization in rivaroxaban authorization, examining how institutional power consolidated therapeutic claims despite device defects.